Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Early assessment of KRAS mutation in cfDNA correlates with risk of progression and death in advanced non-small-cell lung cancer.

British journal of cancer - 1 Jul 2020

Zulato Elisabetta, Attili Ilaria, Pavan Alberto, Nardo Giorgia, Del Bianco Paola, Boscolo Bragadin Andrea, Verza Martina, Pasqualini Lorenza, Pasello Giulia, Fassan Matteo, Calabrese Fiorella, Guarneri Valentina, Amadori Alberto, Conte PierFranco, Indraccolo Stefano, Bonanno Laura

Abstract excerpt

BACKGROUND: Liquid biopsy has the potential to monitor biological effects of treatment. KRAS represents the most commonly mutated oncogene in Caucasian non-small-cell lung cancer (NSCLC). The aim of this study was to explore association of dynamic plasma KRAS genotyping with outcome in advanced NSCLC patients. METHODS: Advanced NSCLC patients were prospectively enrolled. Plasma samples were collected at baseline...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Cell-Free Nucleic Acids

Share to Cohort Studies

Share to Disease Progression

Share to Neoplasm Staging

Share to Proto-Oncogene Proteins p21(ras)

Source

Open in PubMed Open full text

Identifiers

PMID: 32376889
DOI: 10.1038/s41416-020-0833-7
PMCID: PMC7341732

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Early assessment of KRAS mutation in cfDNA correlates with risk of progression and death in advanced non-small-cell lung cancer.PMID 32376889Read ↗

Investigation of transrenal KRAS mutation in late stage NSCLC patients correlates to disease progression.Semantic proximity Read ↗

Plasma-based longitudinal mutation monitoring as a potential predictor of disease progression in subjects with adenocarcinoma in advanced non-small cell lung cancer.Semantic proximity Read ↗

Levels of cell-free DNA and plasma KRAS during treatment of advanced NSCLC.Semantic proximity Read ↗

Monitoring KRAS mutations in circulating DNA and tumor cells using digital droplet PCR during treatment of KRAS-mutated lung adenocarcinoma.Semantic proximity Read ↗

Early Changes in Circulating Cell-Free KRAS G12C Predict Response to Adagrasib in KRAS Mutant Non-Small Cell Lung Cancer Patients.Semantic proximity Read ↗

KRAS mutations in the circulating free DNA (cfDNA) of non-small cell lung cancer (NSCLC) patientsSemantic proximity Read ↗

Detection of KRAS G12/G13 Mutations in Cell Free-DNA by Droplet Digital PCR, Offers Prognostic Information for Patients with Advanced Non-Small Cell Lung Cancer.Semantic proximity Read ↗

The prognostic value of KRAS mutated plasma DNA in advanced non-small cell lung cancer.Semantic proximity Read ↗

Liquid Biopsies in the Screening of Oncogenic Mutations in NSCLC and its Application in Targeted Therapy.Semantic proximity Read ↗

Efficacy of liquid biopsy for disease monitoring and early prediction of tumor progression in EGFR mutation-positive non-small cell lung cancer.Semantic proximity Read ↗

KRAS mutations testing in non-small cell lung cancer: the role of Liquid biopsy in the basal settingSemantic proximity Read ↗

Non-invasive profiling of KRAS mutations in lung cancer using droplet digital polymerase chain reaction.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.